RxDoctor Payments Data

George Cheeseman, MD

Family Medicine · Riverview, FLNPI 1912961269

Payments from drug & device makers

$21,230in general payments, 2019–2025

Across 1,253 payments — averaging $16.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • AbbVie$2K
  • Lilly USA, LLC$1K
  • Novo Nordisk$1K
  • Amarin Pharma, Inc.$1K
  • Pfizer$1K
  • plus $11K from 52 others
$113in research payments, 2019–2025

Across 3 payments — averaging $37.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk$38
  • GSK$38
  • AstraZeneca$38

What the payments were for

  • Travel & lodging$30%
  • Food & beverage$21,148100%
  • Education$780%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca161$2,902
AbbVie(2 entities)97$1,556
Lilly USA, LLC92$1,473
Novo Nordisk81$1,466
Amarin Pharma, Inc.75$1,382
Pfizer83$1,282
Amgen(2 entities)91$1,180
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC48$866
Boehringer Ingelheim56$824
Lucid Diagnostics Inc.41$731
Merck48$705
Kowa Pharmaceuticals America, Inc.45$605
Bayer29$573
GSK31$496
Astellas Pharma US Inc23$473
Esperion Therapeutics, Inc.26$459
Johnson & Johnson23$425
Exact Sciences19$329
Mylan Specialty L.p.11$317
Sanofi-aventis U.S. LLC16$282
Novartis16$247
Vanda Pharmaceuticals Inc.11$244
Abbott13$222
Dexcom, Inc.10$194
Radius Health, Inc.10$188
Biohaven Pharmaceutical Holding Company Ltd.3$182
Phathom Pharmaceuticals, Inc.8$151
Idorsia Pharmaceuticals US Inc7$142
Arbor Pharmaceuticals, Inc.9$135
Eisai Inc.8$133
Sumitomo Pharma America, Inc.9$124
Paratek Pharmaceuticals, Inc.5$82
Shield Therapeutics Inc3$67
QOL Medical, LLC3$62
Azurity Pharmaceuticals, Inc.3$61
E.r. Squibb & Sons, L.L.C.4$59
Biohaven Pharmaceuticals, Inc.3$53
Takeda Pharmaceuticals U.S.A., Inc.3$53
Teva Pharmaceuticals USA, Inc.3$45
Vistapharm, Inc.3$43
Jazz Pharmaceuticals Inc.3$38
Nestle Healthcare Nutrition Inc.2$36
Cequr Corporation1$34
Regeneron Healthcare Solutions, Inc.2$30
Dynavax Technologies Corporation2$29
Boston Scientific1$27
Hologic Sales And Service, LLC1$26
Phadia US Inc.1$24
Optinose US, Inc.1$22
Corcept Therapeutics1$21
Daiichi Sankyo Inc.1$20
Viatris Specialty LLC1$19
Nabriva Therapeutics, PLC1$18
Otsuka America Pharmaceutical, Inc.1$15
Kyowa Kirin, Inc.1$15
Nevro Corp.1$15
Vivus LLC1$14
Tactile Systems Technology Inc1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,230 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$47,085
Medicare patients
96
Services billed
473

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol60$68,644
JardianceEmpagliflozin27$34,543
VascepaIcosapent Ethyl36$33,472
MounjaroTirzepatide23$31,477
OzempicSemaglutide17$24,023
JanuviaSitagliptin Phosphate15$19,360
KerendiaFinerenone13$15,893
Rosuvastatin Calcium442$4,321
Icosapent Ethyl15$1,659
Atorvastatin Calcium161$1,518
Amlodipine Besylate185$1,029
Levothyroxine Sodium86$883
Metformin Hcl120$865
Lisinopril146$803
Telmisartan42$786

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$2,902$68,64460 claims
Boehringer IngelheimJardiance$824$34,54327 claims
Lilly USA, LLCMounjaro$1,473$31,47723 claims
Novo NordiskOzempic$1,466$24,02317 claims
MerckJanuvia$705$19,36015 claims
BayerKerendia$573$15,89313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Riverview

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →